Background: Tuberculosis (TB) causes substantial morbidity and mortality in HIVinfected children. Sample collection and the paucibacillary nature of TB in children makes diagnosis challenging. Rapid diagnostic tools using easily obtained specimens are urgently needed.
Introduction
The WHO estimates there are one million new cases of tuberculosis (TB) and 136 000 TB-associated deaths in children each year [1] . TB-related morbidity and mortality among HIV coinfected children is particularly high [2] . Pediatric TB incidence and mortality are likely underestimated [3] , as evidenced by postmortem studies [4] [5] [6] [7] . Young children are unable to expectorate sputum, the standard specimen for diagnostic workup, and frequently have paucibacillary disease, further delaying the gold standard diagnostic of mycobacterial culture to provide a confirmatory result [8, 9] . HIV adds complexities to TB diagnosis. HIV-infected children have a higher likelihood of comorbidities, and both younger and HIVinfected children are more likely to develop disseminated disease, likely in part because of developmentally or disease-related relative immunosuppresion [10] . Challenges in obtaining respiratory or gastric aspirate samples from children and rapid TB/HIV disease progression prior to obtaining culture results can lead to treatment delays and poor outcomes [11] . Thus, diagnostic tools for rapid detection of TB disease in children using less invasive specimens than sputum or gastric aspirates are urgently needed [12] .
GeneXpert M. tuberculosis (MTB)/RIF (Xpert; Cepheid, Sunnyvale, California, USA) and lateral flow urinary lipoarabinomannan (LAM) are rapid diagnostic tools that may be useful for diagnosing pediatric TB. Xpert is currently endorsed by the WHO for pulmonary TB diagnosis in children and in selected nonpulmonary specimens for extrapulmonary TB diagnosis [13] . The point-of-care urinary LAM assay is sensitive and specific in highly immunosuppressed (CD4 þ 100 cell/ml) HIVinfected adults [14] . WHO recommends urine LAM should be used in HIV-infected adults with low CD4 þ or who are seriously ill, extending the recommendation to HIV-infected children based primarily on adult data [15] . Recent studies suggest stool Xpert may have good diagnostic performance to detect pediatric TB [16] [17] [18] [19] [20] [21] . However, there is a paucity of data regarding stool Xpert and urine LAM in HIV-infected children with severe illness, a population in whom early diagnosis and treatment is lifesaving.
We prospectively assessed the performance of stool Xpert and urine LAM compared with the reference standard of culture and/or Xpert on sputum or gastric aspirates, in a cohort of hospitalized HIV-infected children in Kenya.
Methods
Study setting and participants This TB diagnostic study was nested within the Pediatric Urgent Start of HAART randomized controlled trial (NCT02063880) comparing urgent (<48 h of enrollment) to post-stabilization (7-14 days) initiation of antiretroviral therapy (ART) in HIV-infected children hospitalized for acute illness at four hospitals in Kenya (Kenyatta National Referral Hospital and Mbagathi District Hospital in Nairobi, and Kisumu County Hospital and Jaramogi Oginga Odinga Teaching and Referral Hospital in western Kenya) [22] . Children were eligible if they were aged 12 years or less, HIV-infected, ART-naïve (other than ART for prevention of maternalto-child transmission), and ART eligible according to WHO guidelines [23] . Children with suspected or confirmed central nervous system (CNS) infections were excluded.
Study procedures
Clinical procedures and sample collection At enrollment, children provided early morning sputum samples for Xpert and culture, clean-catch urine, stool, and blood samples. When sputum could not be produced, early morning gastric aspirates were performed by trained medical or clinical officers. A second sputum or gastric aspirate sample was obtained for culture as close to enrollment as possible. Clinical history and sociodemographic information were collected from caregivers, and anthropometric measurements (weight, height, and midupper arm circumference) were assessed. Chest X-rays were read by a hospital radiologist using standardized reporting forms to identify findings suggestive of TB [24] . For tuberculin skin testing (TST), 5 units (0.1 ml) of purified protein derivative (RT23 solution; Sanofi Pasteur, Lyon, France) were injected subcutaneously and induration measured between 48 and 72 h by a study nurse. A positive TSTwas defined as induration of at least 5 mm. For the parent trial, medical history and physical examination were performed at enrollment, 1 and 2 weeks post-ART initiation, then monthly for 6 months.
Sample processing and testing
Sputum/gastric aspirate Xpert and culture Sputum and gastric aspirate samples were sent to the lab within one hour of collection for Xpert testing and mycobacterial culture. For Xpert testing, sample reagent was added to sputum in a 2 : 1 ratio, manually agitated, and 2 ml added to the Xpert cartridge and inserted into the platform. Sputum/gastric aspirates for culture were decontaminated using N-acetyl-L-cysteine and sodium hydroxide-NaOH, centrifuged, suspended in phosphate buffer, and inoculated into liquid culture medium [BACTEC MGIT (mycobacteria growth indicator tube) 960 culture (Becton-Dickinson, Franklin Lakes, New Jersey, USA)]. Flagged bottles were removed, mixed gently, and subcultured to blood agar plates and ZiehlNeelsen smears. Positive Ziehl-Neelsen smears were subcultured onto Löwenstein-Jensen solid medium and evaluated for three additional weeks. Flagged bottles that were Ziehl-Neelsen negative but positive on brain heart infusion agar were deemed contaminated. Unflagged bottles at 60 days were considered negative. Sputum/ gastric aspirate culture and Xpert testing were performed at Lancet Laboratories ß in Nairobi, and Kenya Medical Research Institute/Center for Global Health Research TB laboratory in western Kenya.
Stool Xpert
Stool processing techniques were adapted from procedures developed previously [25] . Immediately after collection, stool samples were suspended in equal volume with sterile phosphate buffered saline solution (0.9%), manually homogenized, refrigerated at 2-58C for at least 12 h, but less than 48 h, then passed through a fine filter maintaining only the liquid. Liquid and supernatant were vortexed and incubated with equal parts NaOH-Nacetyl-L-cysteine and sodium hydroxide, centrifuged twice with phosphate buffer, pellet decanted, and additional phosphate buffer added and vortexed again to resuspend. Sample reagent was added to the resuspended pellet (0.7 ml) in a 2 : 1 ratio, manually agitated and incubated, then used for Xpert testing. Stool Xpert was performed at the University of Nairobi Institute of Tropical and Infectious Diseases laboratory in Nairobi.
Urine lipoarabinomannan
Fresh urine was collected using specimen bags (unless children could produce urine on demand into specimen cups) and tested within 2 h of sample collection using Determine TB LAM Ag Test Cards (Alere, Waltham, Massachusetts, USA) according to manufacturer recommendations [26] . A 60 ml of sample was added to the assay and results read 25-35 min later by a trained laboratory technician. Bar color intensity was graded using the manufacturer reference scale (grade 1 lowest intensity and grade 5 highest intensity). A bar intensity of grade at least 1 was considered positive by manufacturer recommendations at the time of the study.
Statistical analysis
For the primary analyses, we determined diagnostic performance of stool Xpert and urine LAM to detect TB, compared with the gold standard of sputum/gastric aspirate culture on two possible samples. For the intention-to-diagnose approach, stool Xpert and urine LAM were compared with a combined reference of sputum/gastric aspirate culture or Xpert for children with at least one reference test. For the diagnosed-per-protocol approach, stool Xpert and urine LAM were again compared with the combined reference of sputum/ gastric aspirate culture and Xpert, but limited to the subset of children with all three reference tests (two sputum/gastric aspirate culture and one Xpert) according to study protocol. For all scenarios, detection of MTB in at least one reference sample was considered positive. Additionally, we compared stool Xpert and urine LAM with sputum/gastric aspirate Xpert alone. To account for possible differences in diagnostic performance in populations of children with a higher risk of disseminated TB, we stratified results by HIV immunosuppression status using WHO-defined age-specified CD4 þ % cutoffs [27] and age less than 24 months.
Children were categorized as having confirmed, unconfirmed, or unlikely TB based on international consensus clinical case definitions for pediatric TB [28] . For the purposes of this study, response to TB treatment was defined as an increase in weight-for-age Z-score (WAZ) or resolution of the symptom present at the time of TB diagnosis at 6 months follow-up.
Participant characteristics were summarized by frequency and proportion for categorical variables, and by median and interquartile range (IQR) for continuous variables. We estimated the performance of assays by sensitivity, specificity, negative (NPV) and positive predictive value (PPV) using 95% confidence intervals (CI) assuming a binomial distribution. Height-for-age Z-scores, WAZ, and weight-for-height Z-scores were calculated using WHO Anthro software [29] . Data were entered in a Research Electronic Data Capture (REDCap) database [30] and analyzed with STATA version 12 (StataCorp, College Station, Texas, USA).
Ethics approval
Written informed consent was obtained from primary caregivers of all children. Study procedures were approved by the University of Washington Institutional Review Board, Kenyatta National Hospital/University of Nairobi Ethics and Research Committee, and the Kenya Pharmacy and Poisons Board. The study is registered at ClinicalTrials.gov (NCT02063880).
Results
Between April 2013 and May 2015, 181 HIV-infected ART-naïve children were enrolled in the parent clinical trial, 165 of whom had at least one sputum or gastric aspirate collected for culture and/or Xpert (165 Xpert, 164 culture, and 146 with two consecutive culture results; Fig. 1 ). One hundred and forty-eight children had a valid stool Xpert result, 130 had a valid urine LAM result, and 116 had both.
Among 165 children, median age was 24 months (IQR 13-58) and 90 (54.6%) were male (Table 1) . Median CD4 þ % was 14.3% (IQR 8.9-22.0%) and 114 (69.5%) had HIV-associated severe immunosuppression by agedefined CD4 þ % or CD4 þ cell count. Nearly half (58, 46.4%) were acutely malnourishment (WHZ < À2 or MUAC < 12.5 cm). Seven children (4.6%) had a positive TST and 20 (12.4%) reported a TB exposure in the past year. The majority had at least one sign or symptom suggestive of TB (118, 71.5%), with failure to thrive as the most common symptom (103, 64.0%). More than half had an abnormal chest X-ray suggestive of TB (83, 57.2%), and TB treatment was initiated in 61 (37.4%) during the course of the study.
Prevalence of tuberculosis by reference tests and clinical criteria Overall, 13 (7.9%) children had microbiologically confirmed pulmonary TB by reference sputum/gastric aspirates (six positive by both culture and Xpert, four by culture alone, and three by Xpert alone). Seventy-two (43.6%) were considered to have unconfirmed TB, and 80 (48.5%), were considered unlikely to have TB (Table 1) [28] . Figure 1 illustrates the flow of participants with at least one sputum/gastric aspirate culture or Xpert including stool Xpert and urine LAM results by the intention-to-diagnose (at least one reference test performed) and diagnosed-per-protocol (all three reference tests performed: two sputum/gastric aspirate culture and one Xpert) scenarios. Compared with the gold standard of culture, sputum/gastric aspirate Xpert had a sensitivity of 60% (95% CI 26-88%), specificity of 98% (95% CI 94-100%), with PPVand NPVof 67% (95% CI 30-93%) and 97% (95% CI 94-99%), respectively ( Urine LAM negative n = 116 Confirmed TB n = 5
Confirmed TB n = 4 Unconfirmed TB n = 2 Unconfirmed TB n = 55 Unlikely TB n = 7 U n l i k e l y T B n = 57
Stool Xpert Test Performance Intention-to-diagnose a (At least one reference test performed) N = 148 Stool Xpert positive n = 7
Stool Xpert negative n = 141 Confirmed TB n = 7
Confirmed TB n = 4 Unconfirmed TB n = 0 Unconfirmed TB n = 63 Unlikely TB n = 0 U n l i k e l y T B n = 74
Stool Xpert Test Performance Diagnosed-per-protocol b (All 3 reference tests performed) N = 135 Stool Xpert positive n = 7
Stool Xpert negative n = 128 Confirmed TB n = 7
Confirmed TB n = 3 Unconfirmed TB n = 0 Unconfirmed TB n = 58 Unlikely TB n = 0 U n l i k e l y T B n = 67
Urine LAM Test Performance Diagnosed-per-protocol b (All 3 reference tests performed) N = 116 Urine LAM positive n = 13
Urine LAM negative n = 103 Confirmed TB n = 4
Confirmed TB n = 4 Unconfirmed TB n = 2 Unconfirmed TB n = 49 Unlikely TB n = 7 U n l i k e l y T B n = 50
Missing culture #1 result n = 5 Missing culture #2 result n = 9 Missing Urine LAM result n = 0
Missing culture #1 result n = 5 Missing culture #2 result n = 8 Missing Stool Xpert result n = 0 Diagnosed per protocol: All three reference tests (two consecutive cultures and one Xpert) performed on sputum or gastric aspirate. Confirmed, unconfirmed, and unlikely TB by international consensus clinical case definitions for pediatric TB [28] .
of eight children with culture-confirmed TB [sensitivity: 63% (95% CI 25-92%); PPV: 71% (95% CI 29-96%), and classified 137 children as negative (specificity: 98% (95% CI 95-100%); NPV: 98% (95% CI 94-100%)] ( Table 2 ). Stool Xpert performance improved when compared with a combined reference of sputum/gastric aspirate culture or Xpert for children with at least one reference test result available (intention-to-diagnose) and for those children with all three reference tests (diagnosed-per-protocol: two sputum/gastric aspirate cultures and one sputum/gastric aspirates Xpert). Sensitivity marginally increased when compared to Xpert on sputum/gastric aspirates alone (Supplemental Table 1 Table 2) . Specificity remained similar across these groups (Table 2) .
Urine lipoarabinomannan performance
Among 129 children with valid urine LAM results, LAM identified three of nine children with culture-confirmed TB [sensitivity: 43% (95% CI 10-82%); PPV: 21% (95% CI 5-51%), and classified 111 children as negative (specificity: 91% (95% CI 84-95%); NPV: 97% (95% CI 91-99%)] ( Table 2 ). Urine LAM performance improved when compared with a combined reference of sputum/ gastric aspirates culture or Xpert for children with at least one reference test result available (intention-to-diagnose), and for those children with all three reference tests (diagnosed-per-protocol), as well as compared to Xpert on sputum/gastric aspirates alone. However, because of small numbers formal statistical comparison was not performed (Supplemental Table 1 , http://links.lww. com/QAD/B171). Urine LAM was positive in two (3.5%) of 57 children with unconfirmed TB and in seven (10.9%) of 64 children with unlikely TB (Fig. 1) . Median LAM grade was 3 (range 2-5) among five children with confirmed TB, 1.5 (range 1-2) in two with unconfirmed TB, and 2 (range 1-4) in seven children in the unlikely TB category (data not shown). Four children with confirmed TB were urine LAM negative. The performance of urine LAM improved among children with severe HIV immunosuppression [sensitivity: 71% (95% Cl 29-96%), specificity: (93% Cl 85-97%)] compared with those without [sensitivity: 0% (95% Cl 0-84), specificity: 92% (95% Cl 78-98%)] using the combined reference of sputum/gastric aspirate culture or Xpert (Supplemental Table 1 , http://links.lww.com/QAD/B171). LAM had slightly higher sensitivity [67% (95% CI 9-99%)] but lower specificity [87% (95% CI 76-95%)] in children under 24 months of age compared with older children [sensitivity: 50% (95% CI 12-88%), specificity: 97% (95% CI 90-100%)]. Figure 2 shows the overlap of urine LAM and stool Xpert positives with reference sputum/gastric aspirate Xpert or culture. One child who was stool Xpert positive, and an additional child who was urine LAM positive did not have sputum/gastric aspirates collected (Fig. 2) .
Discussion
In this TB diagnostic study of HIV-infected hospitalized children in Kenya, stool Xpert had moderate sensitivity and high specificity for MTB detection compared with a Based on international consensus clinical case definitions for pediatric TB [28] . j Thirteen (7.9%) children had microbiologically confirmed pulmonary TB from reference sputum or gastric aspirates (six positive by culture and Xpert, four by culture alone, and three by Xpert alone). 
þ cell count (<12 months: <1500 cells/ml, 12-35 months: <750 cells/ml, >36 months <350 cells/ml).
reference of sputum/gastric aspirate culture. Urine LAM had lower sensitivity and specificity in general, but improved among children with severe HIV immunosuppression. Importantly, stool Xpert had similar performance to Xpert on sputum/gastric aspirate, the assay currently recommended for rapid detection of TB in children, with the added benefit of utilizing noninvasive sample collection.
Pediatric studies of stool Xpert from South Africa, Zimbabwe, Pakistan, Egypt, as well as a multicenter study (Burkino Faso, Cambodia, Cameroon, and Vietnam) report sensitivities of 31-90% with specificities of 98-100% [16] [17] [18] [19] [20] [21] . In general, sensitivity was higher in HIVinfected compared with HIV-uninfected children, and among children who were hospitalized or with more severe disease [16, 18, 21] . The wide range and variability of sensitivities may be because of different populations studied (HIV infected, HIV uninfected, or combined), differences in sample sizes leading to variably precise estimates, as well as variability in reference standards. Sensitivity of stool Xpert was lower in studies with increased number of reference respiratory/gastric aspirate samples collected. This may favor the reference test when multiple reference samples are collected, and likely underestimates sensitivity of stool Xpert when only one stool sample is collected. The current WHO recommendation for Xpert on respiratory samples for pediatric pulmonary TB was based on a pooled sensitivity of 66% compared with a reference of culture on sputum/gastric aspirates [13] . Our estimated sensitivity of 63-75% for stool Xpert (depending on reference used) is comparable with this and other pooled sensitivity estimates of Xpert on respiratory samples compared with culture [31] . Importantly, the performance of stool Xpert was similar to sputum/gastric aspirate Xpert in our study.
Data regarding the performance of urine LAM in children is inconsistent. In one of the first published reports of pediatric urine LAM testing, Nicol et al. [32] reported poor performance in HIV-infected and HIVuninfected children in South Africa and recommended against its use to diagnose pulmonary TB in children. Their study population may have been less severely ill, as no children recruited from clinic required hospitalization, and no children recruited from hospital died. Subsequent studies in Tanzania have demonstrated improved performance in HIV-infected children compared with HIVuninfected children [33] . The WHO recommendation that LAM be used for the sickest adult patients, primarily HIV-infected inpatients with low CD4 þ cell counts, was extended to children based on the generalization of adult data [15] . In our study of HIV-infected ART-naive children hospitalized for acute illness, performance increased substantially among children with severe immunosuppression (from sensitivity 43-63% in general, to 60-71% when limited to those with severe immunosuppression). LAM specificity did not vary by immunosuppression status in our study (91-93%) but did vary by age (ranging from 85 to 88% in children under 24 months and 96 to 97% in older children). Despite concerns raised in previous studies regarding low specificity [32] , the WHO recommendation to use LAM in immunosuppressed HIV-infected adults, is based on the thought that the net benefit of using LAM in the subpopulation at high risk of mortality, outweighed the harms associated with false positive diagnosis [15] . False positive LAM results can occur from oral flora [34, 35] , candida, and other non-TB mycobacteria [34, 36, 37] . However, an evaluation of LAM among cystic fibrosis patients with known pulmonary non-TB mycobacteria demonstrated low cross-reactivity [38] . Our reference of sputum/gastric aspirate Xpert and mycobacterial culture could also have missed true cases of TB that were detected by LAM either because of the paucibacillary nature of MTB in children or from its extrapulmonary dissemination, contributing to spuriously low estimates of specificity.
Strengths of our study included well characterized presentations and standardization of TB investigations in HIV-infected children. This population of HIVinfected ART-naïve children presenting to hospital with acute illness are most likely to benefit from early diagnosis and treatment of TB. Collecting more than one respiratory sample and testing with both Xpert and culture likely identified more children with TB. All samples were tested in-real time, as opposed to on stored or frozen samples. We provided estimates of performance compared with the gold standard of culture, and in scenarios more reflective of research settings (diagnosedper-protocol requiring all three reference samples). We also summarized performance compared with Xpert on sputum/gastric aspirates and among children with at least one reference sample (intention-to-diagnose) which is likely more reflective of clinical settings, improving the generalizability of our findings.
Exclusion criteria and the younger age of participants may limit the generalizability of our study findings. Children with suspected or confirmed CNS infections were excluded from the parent trial, based on primarily adult data that early ART in the context of CNS coinfection (TB or Cryptococcus spp.) resulted in poor outcomes including increase risk of mortality and immune reconstitution inflammatory syndrome [39, 40] . Our study population was relatively young, with median age of 24 months. Younger children, especially those with HIV, may be more likely to have disseminated disease. Since we used sputum and gastric aspirates as our gold standard, there may have been issues with ascertainment bias, including underdetection of TB in cases of disseminated disease. We were unable to obtain all samples from all participants making comparisons between tests difficult. Samples were missed if a child was too sick or died before a sample could be collected, and this group of children was potentially at highest risk of TB.
Although stool Xpert and urine LAM reduce sample collection issues, further improvements are needed regarding standardization for stool processing. Processing steps prior to running the Xpert test, including allowing the stool and MTB bacilli to homogenize into saline and passing through a filter, make the testing procedures slightly more logistically challenging than processing sputum samples. If stool becomes a recommended sample type for Xpert, additional studies could be done to identify optimal processing of stool samples prior to testing. We did not conduct reference culture testing of stool, urine samples, or additional nonpulmonary samples (including blood), which could have provided important insight into whether stool Xpert and urinary LAM detect extrapulmonary or disseminated TB. Previous pediatric studies of urine LAM have evaluated the performance of the LAM ELISA test, which requires batch testing and significantly more sample processing than the point-ofcare Determine LAM strip used in this study, though may be more sensitive. We did not evaluate the performance of LAM ELISA, and may have missed children who would have been identified by this test. LAM test results were read by a single lab technician.
Children are less likely to benefit from Xpert scale-up in high-burden settings because of sample collection challenges. The current WHO-recommended samples for Xpert include sputum which cannot be feasibly collected in young children, gastric aspirates which require fasting and often hospitalization, and induced sputum which can result in adverse events and potential transmission risk to other patients and healthcare workers. From surveys of 651 pediatric HIV care sites in SubSaharan Africa, less than 10% had capacity to perform induced sputum or gastric aspirates [41] . Continuing developments of rapid TB diagnostics including Xpert Ultra, with increased sensitivity over Xpert and potentially superior to culture, will aid in improved detection of MTB in frequently paucibacillary populations, including children and HIV-infected individuals. However, improvements in detection limits of these diagnostics will not overcome the challenges of pediatric respiratory sample collection. This highlights the need for continued investigation of alternative sample types that can be easily collected for TB detection in children. Although low sensitivity of urine LAM assays compromises its utility as a replacement for mycobacterial culture or Xpert on respiratory samples, the ease of the urine dipstick underscores its potential utility as either an addon test in severely ill HIV-infected children, or in settings where Xpert or culture are not available [42, 43] . This study adds to the growing body of literature supporting the use of stool Xpert and urine LAM in children, and provides data specifically regarding hospitalized HIVinfected ART-naïve children, a particularly high-risk population in whom clinical manifestations of TB are protean and complex, and in which rapid and accurate diagnosis can be lifesaving.
